8th Annual ALS TDI Leadership Summit

Thursday, November 1 2012
9:00 am – 5:00 pm

This event was posted by ALS Therapy Development Institute

Event Inquiries

summit@als.net

Location: Sheraton Boston

8:30AM

Registration & Light Refreshment

9:00AM - 12:00PM

Title: Immune Modulation as a Therapeutic Strategy for ALS
By: Steve Perrin, Ph.D.
Affiliation(s): CEO & Chief Scientific Officer, ALS TDI (USA)  

Title: Propagated Protein Misfolding in ALS: A Target for Effective Therapy
By: Neil Cashman, M.D.
Affiliation(s): Co-Founder & Chief Scientific Officer & Co-Founder, Amorfix Life Sciences, Director, ALS Centre, University of British Columbia (Canada)

 Title: Update on ALS Genetics: Pathways, Prognoses and Prospects
By: Robert Brown, M.D., Ph.D.
Affiliation(s): Chair & Professor, Department of Neurology, University of Massachusetts Medical School (USA)

Title: Neuromuscular Junction Stability in ALS
By: TBA
Affiliation(s): Neurotune AG (Switzerland)

1:00PM

2012 Leadership Awards Presentation
Click here to nominate someone!

2:00PM

Panel Discussion
Iris Löw-Friedrich, M.D., Ph.D.
Executive VP Global Projects and Development & Chief Medical Officer, UCB SA  

Mark Namchuk, Ph.D.

Senior Vice President of Research, Vertex Pharmaceuticals  

John McKew, Ph.D.

Chief, NIH Center for Translational Therapeutics to Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS)  

Lesa Mitchell

Vice President of Innovation & Networks, Kauffman Foundation

Steve Perrin, Ph.D.
CEO & Chief Scientific Officer, ALS TDI

Panel Moderated by: Amy Dockser Marcus, Staff Reporter, The Wall Street Journal  

4P:00M - 6:00PM
Cocktail and Networking Reception

Share MassBio

 

EvaluatePharma

MassBio